Artelo Biosciences (ARTL) Operating Income (2014 - 2025)
Artelo Biosciences (ARTL) posted quarterly Operating Income of -$2.8 million for Q4 2025, up 26.92% year-over-year from -$2.2 million in Q4 2024, and up 9.81% quarter-over-quarter from -$3.1 million in Q3 2025.
Artelo Biosciences (ARTL) Operating Income (2014 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Operating Income for 12 consecutive years, with -$2.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Income rose 26.92% year-over-year to -$2.8 million; the TTM figure through Dec 2025 stood at -$11.4 million (down 12.82% YoY), while the FY2025 annual figure was -$11.4 million, down 12.82% from the prior year.
- Operating Income climbed to -$2.8 million in Q4 2025 per ARTL's latest filing, from -$3.1 million in the prior quarter.
- Across five years, Operating Income topped out at -$1.2 million in Q3 2024 and bottomed at -$3.8 million in Q4 2024.
- Historically, Operating Income has averaged -$2.6 million across 5 years, with a median of -$2.5 million in 2021.
- Annual changes were most pronounced in 2024 — Operating Income soared 54.28% — and 2025, when it plunged 158.49%.
- Artelo Biosciences' Operating Income stood at -$2.6 million in 2021, then tumbled by 36.21% to -$3.5 million in 2022, then rose by 6.79% to -$3.2 million in 2023, then slipped by 17.65% to -$3.8 million in 2024, then rose by 26.92% to -$2.8 million in 2025.
- Business Quant data shows ARTL's Operating Income at -$2.8 million in Q4 2025, -$3.1 million in Q3 2025, and -$3.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Artelo Biosciences | 111,698.23 | -488,301.77 | - | -2.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.79 Mn |
| Sep 30, 2025 | -3.09 Mn |
| Jun 30, 2025 | -3.15 Mn |
| Mar 31, 2025 | -2.38 Mn |
| Dec 31, 2024 | -3.81 Mn |
| Sep 30, 2024 | -1.20 Mn |
| Jun 30, 2024 | -2.51 Mn |
| Mar 31, 2024 | -2.59 Mn |
| Dec 31, 2023 | -3.24 Mn |
| Sep 30, 2023 | -2.61 Mn |
| Jun 30, 2023 | -1.78 Mn |
| Mar 31, 2023 | -2.29 Mn |
| Dec 31, 2022 | -3.48 Mn |
| Sep 30, 2022 | -2.39 Mn |
| Jun 30, 2022 | -2.47 Mn |
| Mar 31, 2022 | -1.95 Mn |
| Nov 30, 2021 | -2.55 Mn |
| Aug 31, 2021 | -3.78 Mn |
| May 31, 2021 | -2.25 Mn |
| Feb 28, 2021 | -1.87 Mn |